Dawn Halkuff Sells 20,000 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Dawn Halkuff sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total value of $121,800.00. Following the completion of the sale, the director owned 95,000 shares of the company’s stock, valued at $578,550. This trade represents a 17.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Price Performance

Xeris Biopharma stock traded up $0.03 during midday trading on Friday, hitting $6.18. The company’s stock had a trading volume of 1,028,207 shares, compared to its average volume of 1,829,779. Xeris Biopharma Holdings, Inc. has a 12 month low of $4.30 and a 12 month high of $10.08. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The stock’s 50-day moving average price is $6.08 and its 200-day moving average price is $6.60. The company has a market capitalization of $1.07 billion, a PE ratio of 103.00 and a beta of 0.78.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. Analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on XERS. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a research report on Monday, March 2nd. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Xeris Biopharma has an average rating of “Hold” and a consensus target price of $10.80.

Institutional Trading of Xeris Biopharma

Several large investors have recently made changes to their positions in the stock. Kestra Advisory Services LLC bought a new stake in Xeris Biopharma during the fourth quarter worth approximately $25,000. AlphaQuest LLC bought a new stake in shares of Xeris Biopharma during the 3rd quarter worth $35,000. KBC Group NV acquired a new position in Xeris Biopharma in the 1st quarter valued at $27,000. Caitong International Asset Management Co. Ltd raised its holdings in Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after acquiring an additional 7,421 shares during the period. Finally, Northwestern Mutual Wealth Management Co. grew its position in shares of Xeris Biopharma by 179.3% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock valued at $63,000 after purchasing an additional 5,000 shares during the last quarter. Institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.